Abstract RAS oncoproteins are drivers of tumor initiation and progression and therapies targeting these directly or their downstream pathways have resulted in unprecedented clinical benefit in cancer. However, recent advances in genomic medicine have revealed that many of the known RAS oncoproteins and cancer-associated mutations are also involved in the pathogenesis of a group of congenital disorders termed RASopathies. Our research is aimed at understanding the role of these oncoproteins at the biochemical and signaling level and we develop novel mouse models that allow us to study RAS oncoproteins in the context of cancer and genetic syndromes. Our recent work has focused on the non-classical RAS protein RIT1, a poorly understood GTPase expressed in most tissues. Pathogenic variants in RIT1 are found somatically in some cancers, such as lung and bladder adenocarcinoma, myeloid leukemias, and in the germline of individuals with Noonan syndrome, the most common RASopathy. Our lab recently demonstrated that, in contrast to classical RAS proteins, RIT1 appears to be mostly regulated through proteasomal degradation by interacting with a complex formed by the substrate adaptor protein LZTR1 and the RING E3 Ubiquitin Ligase Cullin3. We found that this complex is conserved in lower organisms and is necessary for the proper regulation of RIT1 protein levels. In addition, we have also found that RIT1 binds directly to the spindle assembly checkpoint protein MAD2 and its dysregulation leads to increased mitotic length and aneuploidy. Taking advantage of genetically-engineered mice, we have also generated models for RIT1-driven disorders, including Noonan syndrome, lung cancer, and leukemia. Finally, we have recently investigated the mechanisms that underlie RIT1-dependent RAF-MEK-ERK activation and proposed novel therapies that could be used for Noonan syndrome and other cancers. Overall, our work provides novel insights into the regulation, function, and pathogenesis of the RAS-like protein RIT1 Citation Format: Pau Castel. The role of the RAS GTPase RIT1 in RASopathies and cancer [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl):Abstract nr PR05.
Read full abstract